Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2018 Aug 8;46(1):148–158. doi: 10.1007/s00259-018-4096-y

FIGURE 2.

FIGURE 2.

Time-activity curves and number of disintegrations of all the lesions (A, B), all the bone lesions (C, D) and the bone tumors with comparable baseline SUVmax of 68Ga-PSMA-617 activity from 10.0–15.0 after administration of 177Lu-EB-PSMA-617 (red) and 177Lu-PSMA-617 (blue).